STOCK TITAN

Forte Biosciences Gains Nearly 9 % Ownership from Federated Hermes in 13G Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Schedule 13G filing for Forte Biosciences, Inc. (NASDAQ: FBRX) discloses that Federated Hermes, Inc., together with the Voting Shares Irrevocable Trust and members of the Donahue family, holds 1,072,233 common shares of FBRX, representing 8.78 % of the outstanding class as of 30 June 2025. The group reports sole voting and dispositive power over the entire position; no shares are reported as shared voting or shared dispositive power.

The filing is made on Schedule 13G, indicating a passive investment intent rather than an attempt to influence control (Schedule 13D). Item 10 certifications affirm the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control. Each reporting person—Federated Hermes (a Pennsylvania parent holding company), the Voting Shares Irrevocable Trust, and individual trustees Thomas R., Ann C. and J. Christopher Donahue—has signed the certification dated 7 July 2025.

Key takeaways for investors:

  • Institutional Support: Nearly 9 % stake by a well-known asset-manager-led group may suggest confidence in Forte’s prospects.
  • Passive Nature: Schedule 13G signals no activist agenda; limited immediate governance impact.
  • Ownership Threshold: The stake exceeds the 5 % disclosure trigger but remains below 10 %, keeping the group under certain regulatory thresholds (e.g., Hart-Scott-Rodino pre-merger filing).

Positive

  • Institutional confidence: Federated Hermes and related parties disclosed an 8.78 % stake, adding a respected asset manager to Forte’s shareholder base.

Negative

  • None.

Insights

TL;DR – Federated Hermes now owns 8.78 % of FBRX; passive filing, limited short-term impact.

This 13G reveals an institutional holder building a meaningful position in Forte Biosciences. While Federated Hermes is a respected asset manager, the filing is passive, so no governance action is implied. The size—just under 9 %—can provide float stability and potential support for future capital raises, yet it does not cross the 10 % insider threshold that could trigger additional reporting or anti-takeover concerns. Overall impact on valuation is modest; the disclosure mainly informs investors of the updated ownership structure and may enhance perceived institutional credibility.

TL;DR – Passive stake signals confidence but no control intent; governance status quo.

From a governance standpoint, the Donahue-controlled entities consolidate voting at Federated Hermes, giving them sole power over 8.78 % of shares. Because the stake is reported on Schedule 13G, the group certifies no activist purpose, reducing the likelihood of proxy contests or board pressure. Investors should monitor future filings: any switch to Schedule 13D or movement above 10 % would indicate a shift toward an influential role. At present, the disclosure is routine and non-impactful for corporate control dynamics.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Federated Hermes, Inc.
Signature:/s/J. Christopher Donahue
Name/Title:J. Christopher Donahue, as President of Federated Hermes, Inc.
Date:07/07/2025
Voting Shares Irrevocable Trust
Signature:/s/Thomas R. Donahue
Name/Title:Thomas R. Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:07/07/2025
Signature:/s/Ann C. Donahue
Name/Title:Ann C. Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:07/07/2025
Signature:/s/J. Christopher Donahue
Name/Title:J. Christopher Donahue, as Trustee of Voting Shares Irrevocable Trust
Date:07/07/2025
Thomas R. Donahue
Signature:/s/Thomas R. Donahue
Name/Title:Thomas R. Donahue
Date:07/07/2025
Ann C. Donahue
Signature:/s/Ann C. Donahue
Name/Title:Ann C. Donahue
Date:07/07/2025
J. Christopher Donahue
Signature:/s/J. Christopher Donahue
Name/Title:J. Christopher Donahue
Date:07/07/2025

Comments accompanying signature: SEE EXHIBITS 2 AND 3 ATTACHED Exhibit Information EXHIBIT 1 ITEM 3 CLASSIFICATION OF REPORTING PERSONS EXHIBIT 2 AGREEMENT FOR JOINT FILING OF SCHEDULE 13G EXHIBIT 3 POWER OF ATTORNEY

FAQ

How many Forte Biosciences shares does Federated Hermes own?

The group reports 1,072,233 common shares, equal to 8.78 % of outstanding stock.

Is Federated Hermes acting as an activist in FBRX?

No. The filing is on Schedule 13G, indicating a passive investment with no intent to influence control.

What voting power does the reporting group hold over FBRX shares?

They report sole voting and dispositive power over 1,072,233 shares; shared power is 0.

Does the 8.78 % stake trigger additional regulatory requirements?

The stake exceeds the 5 % disclosure threshold but remains below 10 %, avoiding certain heightened regulatory obligations.

Who signed the Schedule 13G for Federated Hermes?

Signatures include J. Christopher Donahue (President, Federated Hermes) and trustees Thomas R., Ann C., and J. Christopher Donahue for the Voting Shares Irrevocable Trust.
Forte Biosciences Inc

NASDAQ:FBRX

FBRX Rankings

FBRX Latest News

FBRX Latest SEC Filings

FBRX Stock Data

366.54M
10.83M
Biotechnology
Pharmaceutical Preparations
Link
United States
DALLAS